Crosstalk Between Insulin-like Growth Factor (IGF) and Epidermal Growth Factor (EGF) Receptors

[1]  Melissa L. Johnson,et al.  Emerging targeted therapies for breast cancer. , 2007, Hematology/oncology clinics of North America.

[2]  Edward S. Kim,et al.  Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. , 2006, Cancer research.

[3]  A. Huether,et al.  Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. , 2006, World journal of gastroenterology.

[4]  J. Baselga,et al.  The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy , 2006, Clinical Cancer Research.

[5]  B. Leyland-Jones,et al.  Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. , 2006, Cancer research.

[6]  H. Tsuda,et al.  Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer , 2006, Modern Pathology.

[7]  Adrian V. Lee,et al.  Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. , 2006, Cancer research.

[8]  H. Modjtahedi,et al.  Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. , 2006, International journal of oncology.

[9]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[10]  F. Giorgino,et al.  The IGF-I/IGF-I receptor pathway: Implications in the Pathophysiology of Thyroid Cancer. , 2005, Current medicinal chemistry.

[11]  J. Baselga,et al.  Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Booker,et al.  Molecular interactions of the IGF system. , 2005, Cytokine & growth factor reviews.

[13]  I. Ellis,et al.  Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. , 2005, Endocrine-related cancer.

[14]  D. Hicklin,et al.  A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity* , 2005, Journal of Biological Chemistry.

[15]  M. Pollak,et al.  Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells , 2005, Breast Cancer Research.

[16]  P. Pauwels,et al.  A recombinant humanized anti‐insulin‐like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti‐epidermal growth factor receptor therapy against human cancer xenografts , 2005, International journal of cancer.

[17]  R. Nicholson,et al.  Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. , 2004, Endocrine-related cancer.

[18]  P M Harari,et al.  Epidermal growth factor receptor inhibition strategies in oncology. , 2004, Endocrine-related cancer.

[19]  Y. M. Lee,et al.  Synergistic induction of in vivo angiogenesis by the combination of insulin-like growth factor-II and epidermal growth factor. , 2004, Oncology reports.

[20]  G. Schweizer-Groyer,et al.  An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. , 2004, Biochemical pharmacology.

[21]  M. Weller,et al.  Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. , 2004, Biochemical and biophysical research communications.

[22]  I. Frahm,et al.  Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity , 2004, Oncogene.

[23]  Stefano Fumagalli,et al.  S6K1−/−/S6K2−/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway , 2004, Molecular and Cellular Biology.

[24]  S. Averbuch,et al.  Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors , 2004, British Journal of Cancer.

[25]  P. Bohlen,et al.  Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody* , 2004, Journal of Biological Chemistry.

[26]  M. Pollak,et al.  Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells , 2004, International journal of cancer.

[27]  Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. , 2003, Endocrine-related cancer.

[28]  J. Ricort,et al.  Growth factor-specific regulation of insulin receptor substrate-1 expression in MCF-7 breast carcinoma cells: effects on the insulin-like growth factor signaling pathway. , 2003, Endocrinology.

[29]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[30]  L. Ellis,et al.  Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. , 2003, The American journal of pathology.

[31]  J. Baselga,et al.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  E. Vokes,et al.  Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Pollak,et al.  Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[35]  Antonio J. Grillo-López,et al.  Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma , 2002, Expert review of anticancer therapy.

[36]  R. Herbst.  Targeted therapy in non-small-cell lung cancer. , 2002, Oncology.

[37]  S. Korsmeyer,et al.  Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor* , 2002, The Journal of Biological Chemistry.

[38]  T. Wood,et al.  Requirement for IGF-I in epidermal growth factor-mediated cell cycle progression of mammary epithelial cells. , 2002, Endocrinology.

[39]  A. Hassan,et al.  The insulin-like growth factor system as a therapeutic target in colorectal cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  Y. Lu,et al.  Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.

[41]  D. Hadsell,et al.  Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. , 2001, Endocrinology.

[42]  M. Linenberger,et al.  Mylotarg: antibody-targeted chemotherapy comes of age , 2001, Current opinion in oncology.

[43]  J. Baselga.  Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials , 2001, Oncology.

[44]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[45]  P. Black,et al.  Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  R. DePinho,et al.  Malignant glioma: genetics and biology of a grave matter. , 2001, Genes & development.

[47]  J. Testa,et al.  AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. , 2001, Cancer research.

[48]  R. Schmidt-Ullrich,et al.  The relative role of ErbB1–4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells , 2001, Oncogene.

[49]  Hans J. Berkel,et al.  Free insulin‐like growth factor‐I and breast cancer risk , 2001 .

[50]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[51]  P. Elizalde,et al.  Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells , 2001, Oncogene.

[52]  M. Karas,et al.  The Potentiation of Estrogen on Insulin-like Growth Factor I Action in MCF-7 Human Breast Cancer Cells Includes Cell Cycle Components* , 2000, The Journal of Biological Chemistry.

[53]  G. Adessi,et al.  Cell-associated insulin-like growth factor-binding proteins inhibit insulin-like growth factor-I-induced endometrial cancer cell proliferation. , 2000, Cellular and molecular biology.

[54]  G. Nilsson,et al.  Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. , 2000, Cancer research.

[55]  W. Hong,et al.  Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells , 2000, Oncogene.

[56]  Hong Zhang,et al.  Insulin-like Growth Factor I-mediated Degradation of Insulin Receptor Substrate-1 Is Inhibited by Epidermal Growth Factor in Prostate Epithelial Cells* , 2000, The Journal of Biological Chemistry.

[57]  Adrian V. Lee,et al.  Insulin-Like Growth Factor I-Induced Degradation of Insulin Receptor Substrate 1 Is Mediated by the 26S Proteasome and Blocked by Phosphatidylinositol 3′-Kinase Inhibition , 2000, Molecular and Cellular Biology.

[58]  K. Ang,et al.  In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  M. Weller,et al.  PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis , 1999, Oncogene.

[60]  J. Swantek,et al.  Prolonged activation of ERK2 by epidermal growth factor and other growth factors requires a functional insulin-like growth factor 1 receptor. , 1999, Endocrinology.

[61]  E. Wilker,et al.  Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulin‐like growth factor‐1 receptor in the epidermis of transgenic mice , 1999, Molecular carcinogenesis.

[62]  J. Woodburn,et al.  The epidermal growth factor receptor and its inhibition in cancer therapy. , 1999, Pharmacology & therapeutics.

[63]  K. W. Kim,et al.  Insulin-like growth factor II (IGF-II) secreted from HepG2 human hepatocellular carcinoma cells shows angiogenic activity. , 1998, Cancer letters.

[64]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[65]  D. Tindall,et al.  Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line , 1998, The Prostate.

[66]  G. Shulman,et al.  Disruption of IRS-2 causes type 2 diabetes in mice , 1998, Nature.

[67]  Adrian V. Lee,et al.  Igf system components as prognostic markers in breast cancer , 1998, Breast Cancer Research and Treatment.

[68]  R. Pollock,et al.  Epidermal growth factor receptor and insulin-like growth factor-I receptor expression and function in human soft-tissue sarcoma cells. , 1998, International journal of oncology.

[69]  M. Korc,et al.  Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. , 1998, The Journal of clinical investigation.

[70]  K. W. Kim,et al.  Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. , 1998, Cancer research.

[71]  D. Tweardy,et al.  Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells , 1997, Oncogene.

[72]  D. Jackson,et al.  The insulin-like growth factor II/mannose 6-phosphate receptor is required for proliferin-induced angiogenesis. , 1996, Endocrinology.

[73]  M. Kitagawa,et al.  Thyrotropin induces G1 cyclin expression and accelerates G1 phase after insulin-like growth factor I stimulation in FRTL-5 cells. , 1996, Endocrinology.

[74]  M. Lynch,et al.  Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression. , 1996, British Journal of Cancer.

[75]  G. Werther,et al.  Insulin-like growth factor-I and epidermal growth factor regulate insulin-like growth factor binding protein-3 (IGFBP-3) in the human keratinocyte cell line HaCaT. , 1995, The Journal of investigative dermatology.

[76]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[77]  C. Kahn,et al.  Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene , 1994, Nature.

[78]  T. Yagi,et al.  Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1 , 1994, Nature.

[79]  D. Coppola,et al.  A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor , 1994, Molecular and cellular biology.

[80]  R. Furlanetto,et al.  Insulin-like growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro. , 1994, Molecular endocrinology.

[81]  D. Noonan,et al.  Expression and function of the insulin‐like growth factor I system in human non‐small‐cell lung cancer and normal lung cell lines , 1994, International journal of cancer.

[82]  J. Pouysségur,et al.  Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[83]  G. Thomas.  MAP kinase by any other name smells just as sweet , 1992, Cell.

[84]  A. L. Cahill,et al.  Activation of a Microtubule‐Associated Protein‐2 Kinase by Insulin‐Like Growth Factor‐I in Bovine Chromaffin Cells , 1991, Journal of neurochemistry.

[85]  Nancy Y. Ip,et al.  ERKs: A family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF , 1991, Cell.

[86]  D. Hill,et al.  FETAL GROWTH CONTROL: THE ROLE OF INSULIN AND RELATED PEPTIDES , 1984, Clinical endocrinology.

[87]  O. Larsson,et al.  Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[88]  C. Singer,et al.  Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[89]  P. Fasching,et al.  A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer , 2004, Breast Cancer Research and Treatment.

[90]  I. Z̆ofková.  Pathophysiological and clinical importance of insulin-like growth factor-I with respect to bone metabolism. , 2003, Physiological research.

[91]  D. Yee,et al.  The type I IGF receptor as a target for breast cancer therapy. , 2003, Breast disease.

[92]  B. Cheson.  Bexxar (Corixa/GlaxoSmithKline). , 2002, Current opinion in investigational drugs.

[93]  Arnab Chakravarti,et al.  Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. , 2002, Cancer research.

[94]  D. Roith.  Insulin-like Growth Factors , 2024 .

[95]  S. Plymate,et al.  Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. , 2001, Endocrinology.

[96]  L. Gordon,et al.  Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  M. White,et al.  The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. , 1998, Recent progress in hormone research.

[98]  D. Leroith,et al.  Insulin-Like Growth Factors and Their Receptors in Normal Physiology and Pathological States , 1993, The Journal of pediatric endocrinology.